China Archives -

On the same day as it reported encouraging new data for its cancer drug Trodelvy, Gilead Sciences has

On heels of new data, Gilead pays $455m for Asian Trodelvy rights

https://pharmaphorum.com/news/on-heels-of-new-data-gilead-pays-455m-for-asian-trodelvy-rights/

Market Access/ News/ News/ News/ Oncology

Sanofi looks east with €300m Innovent cancer alliance

Phil Taylor China, immuno-oncology, Innovent, Oncology, partnering, Sanofi, sintilimab, tusamitamab ravtansine 0 Comment

Sanofi is making a €300 million investment in Chinese biotech Innovent as part of a collaboration to bring

Sanofi looks east with €300m Innovent cancer alliance

https://pharmaphorum.com/news/sanofi-looks-east-with-e300m-innovent-cancer-alliance/

News/ News/ R&D

Chinese biotech Sironax raises $200m for RIPK1 pipeline

Phil Taylor China, Eli Lilly, financing, Genfleet Therapeutics, GlaxoSmithKline, Immunology and inflammation, Rigel Pharmaceuticals, RIPK1, Sanofi, Sironax 0 Comment

Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire

Chinese biotech Sironax raises $200m for RIPK1 pipeline

https://pharmaphorum.com/news/chinese-biotech-sironax-raises-200m-for-ripk1-pipeline/

Market Access/ News/ News/ News/ Oncology

Simcere gets China okay for G1’s bone marrow protector Cosela

Phil Taylor China, Cosela, G1 Therapeutics, Oncology, regulatory approval, Simcere Pharmaceutical 0 Comment

China’s Simcere Pharmaceutical has been granted approval in its home market for Cosela, a drug designed to limit

Simcere gets China okay for G1’s bone marrow protector Cosela

https://pharmaphorum.com/news/simcere-gets-china-okay-for-g1s-bone-marrow-protector-cosela/

News/ News/ Sales and Marketing

Bayer grabs Chinese okay for CKD therapy Kerendia

Phil Taylor Bayer, China, chronic kidney disease, Kerendia, regulatory approval 0 Comment

On the heels of approvals in the US, Europe and Japan, Bayer’s Kerendia for chronic kidney disease (CKD)

Bayer grabs Chinese okay for CKD therapy Kerendia

https://pharmaphorum.com/news/bayer-grabs-chinese-okay-for-ckd-therapy-kerendia/

Market Access/ Views & Analysis/ Views and analysis

US frets over pharma supply chain security

Ben Hargreaves biologics, China, fda, pharma, US 0 Comment

The pandemic highlighted how fragile the global manufacturing network is, as supply of certain products was limited and

US frets over pharma supply chain security

https://pharmaphorum.com/market-access-2/us-frets-over-pharma-supply-chain-security/

Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

FDA’s treatment of China-developed drugs spurs demands for multiregional clinical trials

Ben Hargreaves biologic medicines, China, fda, Lilly 0 Comment

China’s emergence as an R&D powerhouse means that the country is quickly adding a number of drug candidates

FDA’s treatment of China-developed drugs spurs demands for multiregional clinical trials

https://pharmaphorum.com/market-access-2/fdas-treatment-of-china-developed-drugs-spurs-demands/

Market Access/ News/ News/ News/ Oncology

FDA says no to two more China-developed cancer drugs

Phil Taylor China, Coherus, fda, HutchMed, immuno-oncology, Oncology, regulatory 0 Comment

The FDA has declined to approve two more cancer therapies developed by drugmakers based in China, in what

FDA says no to two more China-developed cancer drugs

https://pharmaphorum.com/news/fda-says-no-to-two-more-china-developed-cancer-drugs/

Doctor using mobile smart phone, work on laptop computer

Digital/ News/ News

Digital health funding boom continues as ETAO cuts SPAC deal

Phil Taylor China, digital, digital health, ETAO International, financing, SPAC, telehealth 0 Comment

Chinese digital health firm ETAO International will go public via a merger with a blank cheque company that

Digital health funding boom continues as ETAO cuts SPAC deal

https://pharmaphorum.com/news/digital-health-financing-boom-continues-as-etao-cuts-spac-deal/

Trending

China

Login